澳洲幸运5官方开奖结果体彩网

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

Published February 18, 2025

11:27 AM EST

Teva — SOPA Images / Contributor / Getty Images

Key Takeaways

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders.
The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea.
Teva and Alvotech have been working together in a strategic partnership since 2020.

Teva Pharmaceutical Industries (TEVA) and partner Alvotech (ALVO) said the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) agreed to review their AVTO6 treatment for eye disorders.

The treatment could compete with Regeneron Pharmaceuticals’ (REGN) Eylea, which is widely used to treat diseases such as neovascular, or “wet,” Age-related Macular Degeneration (AMD), macular edema, and diabetic retinopathy. It had 2024 sales in the U.S. of $4.77 billion, according to Regeneron.

Teva and Alvotech began a strategic partnership in August 2020 to collaborate in the U.S. biosimilar drug market. They are currently wo𓃲rking on a higher-dose version of the medicine to compete with Eylea HD.

Teva Pharmaceutical Industries shares climbed about 3% Tuesday morning following the release, while Alvotech shares ticked 0.8% lower. Regeneron Pharmaceuticals were up about 1.7%.

Do you have a news tip for Investopedia reporters? Please email us at

澳洲幸运5官方开奖结果体彩网:tips@cnjem.com

Article Sources

Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

Teva Pharmaceutical Industries. "."
Regeneron. "."
Alvotech. "."

Compare Accounts

The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.